$8.69
+3.45%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$8.29
From 52W high−34.46%
Volume1308.00
Market cap$1.65B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$8.29
From 52W high
−34.46%
Volume
1308.00
Market cap
$1.65B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.0x
P/E (TTM)
—
RSI (14)
37.6
MomentumView details →
1D Return
+3.45%
YTD Return
+839.46%
SummaryUpdated Jun 1, 2026
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company founded in 2014 and headquartered in Redwood City, California. The company focuses on developing novel targeted therapies specifically designed to treat RAS-addicted cancers, a historically challenging area in oncology that represents a significant unmet medical need. Since its inception, Revolution Medicines has built a comprehensive pipeline of investigational drugs targeting various RAS mutations, positioning itself as a specialized player in the precision oncology space.
Similar companies
Latest newsMore news →
The EUROPEAN MEDICINES AGENCY’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.4d agoRevolution Medicines, Inc. began treating patients in the Phase 3 RASolute 309 trial evaluating RASONQUE (daraxonrasib) plus zoldonrasib as first-line treatment for metastatic RAS G12D pancreatic adenocarcinoma.15d agoIn late August 2026, the U.S. Food and Drug Administration approved daraxonrasib, a new KRAS-targeting therapeutic for previously treated pancreatic cancer developed by Revolution Medicines.29d ago